BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sipponen T, Kärkkäinen P, Savilahti E, Kolho K, Nuutinen H, Turunen U, Färkkilä M. Correlation of faecal calprotectin and lactoferrin with an endoscopic score for Crohn’s disease and histological findings. Alimentary Pharmacology & Therapeutics 2008;28:1221-9. [DOI: 10.1111/j.1365-2036.2008.03835.x] [Cited by in Crossref: 210] [Cited by in F6Publishing: 210] [Article Influence: 15.0] [Reference Citation Analysis]
Number Citing Articles
1 Anjum MR, Chalmers J, Hamid R, Rajoriya N. COVID-19: Effect on gastroenterology and hepatology service provision and training: Lessons learnt and planning for the future. World J Gastroenterol 2021; 27(44): 7625-7648 [PMID: 34908803 DOI: 10.3748/wjg.v27.i44.7625] [Reference Citation Analysis]
2 Jusué V, Chaparro M, Gisbert JP. Accuracy of fecal calprotectin for the prediction of endoscopic activity in patients with inflammatory bowel disease. Dig Liver Dis 2018;50:353-9. [PMID: 29396129 DOI: 10.1016/j.dld.2017.12.022] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 3.2] [Reference Citation Analysis]
3 Molander P, af Björkesten CG, Mustonen H, Haapamäki J, Vauhkonen M, Kolho KL, Färkkilä M, Sipponen T. Fecal calprotectin concentration predicts outcome in inflammatory bowel disease after induction therapy with TNFα blocking agents. Inflamm Bowel Dis. 2012;18:2011-2017. [PMID: 22223566 DOI: 10.1002/ibd.22863] [Cited by in Crossref: 119] [Cited by in F6Publishing: 114] [Article Influence: 11.9] [Reference Citation Analysis]
4 Louis E. Fecal calprotectin: towards a standardized use for inflammatory bowel disease management in routine practice. J Crohns Colitis. 2015;9:1-3. [PMID: 25536671 DOI: 10.1093/ecco-jcc/jju012] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.6] [Reference Citation Analysis]
5 Okazaki N, Inokuchi T, Hiraoka S, Ohmori M, Takashima S, Takei D, Sugihara Y, Takahara M, Harada K, Kawano S, Okada H, Kato J. Findings of Retrograde Contrast Study Through Double-balloon Enteroscopy Predict the Risk of Bowel Resections in Patients with Crohnʼs Disease with Small Bowel Stenosis: . Inflammatory Bowel Diseases 2017;23:2097-103. [DOI: 10.1097/mib.0000000000001175] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.2] [Reference Citation Analysis]
6 af Björkesten C, Nieminen U, Sipponen T, Turunen U, Arkkila P, Färkkilä M. Mucosal healing at 3 months predicts long-term endoscopic remission in anti-TNF-treated luminal Crohn's disease. Scandinavian Journal of Gastroenterology 2013;48:543-51. [DOI: 10.3109/00365521.2013.772230] [Cited by in Crossref: 46] [Cited by in F6Publishing: 48] [Article Influence: 5.1] [Reference Citation Analysis]
7 Burri E, Beglinger C. The use of fecal calprotectin as a biomarker in gastrointestinal disease. Expert Rev Gastroenterol Hepatol. 2014;8:197-210. [PMID: 24345070 DOI: 10.1586/17474124.2014.869476] [Cited by in Crossref: 45] [Cited by in F6Publishing: 39] [Article Influence: 5.0] [Reference Citation Analysis]
8 Zittan E, Kelly OB, Kirsch R, Milgrom R, Burns J, Nguyen GC, Croitoru K, Van Assche G, Silverberg MS, Steinhart AH. Low Fecal Calprotectin Correlates with Histological Remission and Mucosal Healing in Ulcerative Colitis and Colonic Crohn's Disease. Inflamm Bowel Dis. 2016;22:623-630. [PMID: 26829408 DOI: 10.1097/mib.0000000000000652] [Cited by in Crossref: 93] [Cited by in F6Publishing: 35] [Article Influence: 15.5] [Reference Citation Analysis]
9 Minderhoud IM, Steyerberg EW, van Bodegraven AA, van der Woude CJ, Hommes DW, Dijkstra G, Fidder HH, Schwartz MP, Oldenburg B. Predicting Endoscopic Disease Activity in Crohn's Disease: A New and Validated Noninvasive Disease Activity Index (The Utrecht Activity Index). Inflamm Bowel Dis 2015;21:2453-9. [PMID: 26181428 DOI: 10.1097/MIB.0000000000000507] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
10 Therrien A, Chapuy L, Bsat M, Rubio M, Bernard G, Arslanian E, Orlicka K, Weber A, Panzini BP, Dorais J, Bernard EJ, Soucy G, Bouin M, Sarfati M. Recruitment of activated neutrophils correlates with disease severity in adult Crohn's disease. Clin Exp Immunol 2019;195:251-64. [PMID: 30347439 DOI: 10.1111/cei.13226] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
11 Yamamoto T, Shimoyama T. Monitoring and detection of disease recurrence after resection for Crohn’s disease: the role of non-invasive fecal biomarkers. Expert Review of Gastroenterology & Hepatology 2017;11:899-909. [DOI: 10.1080/17474124.2017.1356226] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.2] [Reference Citation Analysis]
12 Barnes EL, Burakoff R. New Biomarkers for Diagnosing Inflammatory Bowel Disease and Assessing Treatment Outcomes. Inflamm Bowel Dis 2016;22:2956-65. [PMID: 27763951 DOI: 10.1097/MIB.0000000000000903] [Cited by in Crossref: 17] [Cited by in F6Publishing: 6] [Article Influence: 4.3] [Reference Citation Analysis]
13 Cerrillo E, Beltrán B, Pous S, Echarri A, Gallego JC, Iborra M, Pamies J, Nos P. Fecal Calprotectin in Ileal Crohnʼs Disease: Relationship with Magnetic Resonance Enterography and a Pathology Score. Inflammatory Bowel Diseases 2015;21:1572-9. [DOI: 10.1097/mib.0000000000000404] [Cited by in Crossref: 41] [Cited by in F6Publishing: 19] [Article Influence: 5.9] [Reference Citation Analysis]
14 Copova I, Hradsky O, Zarubova K, Gonsorcikova L, Potuznikova K, Lerchova T, Nevoral J, Bronsky J. Fecal calprotectin is not a clinically useful marker for the prediction of the early nonresponse to exclusive enteral nutrition in pediatric patients with Crohn disease. Eur J Pediatr 2018;177:1685-93. [DOI: 10.1007/s00431-018-3228-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
15 Simon EG, Wardle R, Thi AA, Eldridge J, Samuel S, Moran GW. Does fecal calprotectin equally and accurately measure disease activity in small bowel and large bowel Crohn's disease? - a systematic review. Intest Res. 2019;. [PMID: 30704158 DOI: 10.5217/ir.2018.00114] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
16 Magro F, Lopes SI, Lopes J, Portela F, Cotter J, Lopes S, Moreira MJ, Lago P, Peixe P, Albuquerque A, Rodrigues S, Silva MR, Monteiro P, Lopes C, Monteiro L, Macedo G, Veloso L, Camila C, Afonso J, Geboes K, Carneiro F; Portuguese IBD group [GEDII]. Histological Outcomes and Predictive Value of Faecal Markers in Moderately to Severely Active Ulcerative Colitis Patients Receiving Infliximab. J Crohns Colitis 2016;10:1407-16. [PMID: 27226417 DOI: 10.1093/ecco-jcc/jjw112] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 5.0] [Reference Citation Analysis]
17 Abraham BP, Ahmed T, Ali T. Inflammatory Bowel Disease: Pathophysiology and Current Therapeutic Approaches. In: Greenwood-van Meerveld B, editor. Gastrointestinal Pharmacology. Cham: Springer International Publishing; 2017. pp. 115-46. [DOI: 10.1007/164_2016_122] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 5.4] [Reference Citation Analysis]
18 Aomatsu T, Imaeda H, Matsumoto K, Kimura E, Yoden A, Tamai H, Fujiyama Y, Mizoguchi E, Andoh A. Faecal chitinase 3-like-1: a novel biomarker of disease activity in paediatric inflammatory bowel disease: Faecal chitinase 3-like-1 and IBD. Alimentary Pharmacology & Therapeutics 2011;34:941-8. [DOI: 10.1111/j.1365-2036.2011.04805.x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 2.1] [Reference Citation Analysis]
19 Lamb CA, Kennedy NA, Raine T, Hendy PA, Smith PJ, Limdi JK, Hayee B, Lomer MCE, Parkes GC, Selinger C, Barrett KJ, Davies RJ, Bennett C, Gittens S, Dunlop MG, Faiz O, Fraser A, Garrick V, Johnston PD, Parkes M, Sanderson J, Terry H;  IBD guidelines eDelphi consensus group; Gaya DR, Iqbal TH, Taylor SA, Smith M, Brookes M, Hansen R, Hawthorne AB. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut. 2019;68:s1-s106. [PMID: 31562236 DOI: 10.1136/gutjnl-2019-318484] [Cited by in Crossref: 361] [Cited by in F6Publishing: 297] [Article Influence: 120.3] [Reference Citation Analysis]
20 Boube M, Laharie D, Nancey S, Hebuterne X, Fumery M, Pariente B, Roblin X, Peyrin-biroulet L, Minet-quinard R, Pereira B, Bommelaer G, Buisson A. Variation of faecal calprotectin level within the first three months after bowel resection is predictive of endoscopic postoperative recurrence in Crohn's disease. Digestive and Liver Disease 2020;52:740-4. [DOI: 10.1016/j.dld.2020.03.020] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
21 Marlicz W, Skonieczna-Żydecka K, Dabos KJ, Łoniewski I, Koulaouzidis A. Emerging concepts in non-invasive monitoring of Crohn's disease. Therap Adv Gastroenterol 2018;11:1756284818769076. [PMID: 29707039 DOI: 10.1177/1756284818769076] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
22 Montalto M, Gallo A, Ianiro G, Santoro L, D’Onofrio F, Ricci R, Cammarota G, Covino M, Vastola M, Gasbarrini A, Gasbarrini G. Can chronic gastritis cause an increase in fecal calprotectin concentrations? World J Gastroenterol 2010; 16(27): 3406-3410 [PMID: 20632443 DOI: 10.3748/wjg.v16.i27.3406] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
23 Soubières AA, Poullis A. Emerging Biomarkers for the Diagnosis and Monitoring of Inflammatory Bowel Diseases. Inflamm Bowel Dis. 2016;22:2016-2022. [PMID: 27416044 DOI: 10.1097/mib.0000000000000836] [Cited by in Crossref: 22] [Cited by in F6Publishing: 9] [Article Influence: 5.5] [Reference Citation Analysis]
24 Manolakis AC, Kapsoritakis AN, Tiaka EK, Potamianos SP. Calprotectin, calgranulin C, and other members of the s100 protein family in inflammatory bowel disease. Dig Dis Sci 2011;56:1601-11. [PMID: 21203903 DOI: 10.1007/s10620-010-1494-9] [Cited by in Crossref: 53] [Cited by in F6Publishing: 45] [Article Influence: 4.8] [Reference Citation Analysis]
25 Mosli M, Al Beshir M, Al-Judaibi B, Al-Ameel T, Saleem A, Bessissow T, Ghosh S, Almadi M. Advances in the diagnosis and management of inflammatory bowel disease: challenges and uncertainties. Saudi J Gastroenterol 2014;20:81-101. [PMID: 24705146 DOI: 10.4103/1319-3767.129473] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
26 Maaser C, Sturm A, Vavricka SR, Kucharzik T, Fiorino G, Annese V, Calabrese E, Baumgart DC, Bettenworth D, Borralho Nunes P, Burisch J, Castiglione F, Eliakim R, Ellul P, González-Lama Y, Gordon H, Halligan S, Katsanos K, Kopylov U, Kotze PG, Krustinš E, Laghi A, Limdi JK, Rieder F, Rimola J, Taylor SA, Tolan D, van Rheenen P, Verstockt B, Stoker J; European Crohn’s and Colitis Organisation [ECCO] and the European Society of Gastrointestinal and Abdominal Radiology [ESGAR]. ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD, detection of complications. J Crohns Colitis 2019;13:144-64. [PMID: 30137275 DOI: 10.1093/ecco-jcc/jjy113] [Cited by in Crossref: 313] [Cited by in F6Publishing: 263] [Article Influence: 104.3] [Reference Citation Analysis]
27 Boland BS, Boyle DL, Sandborn WJ, Firestein GS, Levesque BG, Hillman J, Zhang B, Proudfoot J, Eckmann L, Ernst PB, Rivera-Nieves J, Pola S, Copur-Dahi N, Zou G, Chang JT. Validation of gene expression biomarker analysis for biopsy-based clinical trials in Crohn's disease. Inflamm Bowel Dis 2015;21:323-30. [PMID: 25545378 DOI: 10.1097/MIB.0000000000000264] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
28 Faubion WA, Fletcher JG, O'byrne S, Feagan BG, de Villiers WJ, Salzberg B, Plevy S, Proctor DD, Valentine JF, Higgins PD, Harris JM, Diehl L, Wright L, Tew GW, Luca D, Basu K, Keir ME. EMerging BiomARKers in Inflammatory Bowel Disease (EMBARK) Study Identifies Fecal Calprotectin, Serum MMP9, and Serum IL-22 as a Novel Combination of Biomarkers for Crohn's Disease Activity: Role of Cross-Sectional Imaging. American Journal of Gastroenterology 2013;108:1891-900. [DOI: 10.1038/ajg.2013.354] [Cited by in Crossref: 70] [Cited by in F6Publishing: 67] [Article Influence: 7.8] [Reference Citation Analysis]
29 Pouw RE, Bisschops R, Gecse KB, de Hertogh G, Iacucci M, Rutter M, Barret M, Biermann K, Czakó L, Hucl T, Jansen M, Savarino E, Spaander MCW, Schmidt PT, Dinis-Ribeiro M, Vieth M, van Hooft JE. Endoscopic tissue sampling - Part 2: Lower gastrointestinal tract. European Society of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy 2021;53:1261-73. [PMID: 34715702 DOI: 10.1055/a-1671-6336] [Reference Citation Analysis]
30 Berrill JW, Gallacher J, Hood K, Green JT, Matthews SB, Campbell AK, Smith A. An observational study of cognitive function in patients with irritable bowel syndrome and inflammatory bowel disease. Neurogastroenterol Motil. 2013;25:918-e704. [PMID: 23981191 DOI: 10.1111/nmo.12219] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 2.4] [Reference Citation Analysis]
31 Benitez JM, Meuwis MA, Reenaers C, Van Kemseke C, Meunier P, Louis E. Role of endoscopy, cross-sectional imaging and biomarkers in Crohn’s disease monitoring. Gut. 2013;62:1806-1816. [PMID: 24203056 DOI: 10.1136/gutjnl-2012-303957] [Cited by in Crossref: 70] [Cited by in F6Publishing: 60] [Article Influence: 8.8] [Reference Citation Analysis]
32 Primas C, Hopf G, Reinisch S, Baumann L, Novacek G, Reinisch W, Vogelsang H. Role of fecal calprotection in predicting endoscopic recurrence in postoperative Crohn's disease. Scand J Gastroenterol 2021;:1-6. [PMID: 34314308 DOI: 10.1080/00365521.2021.1955965] [Reference Citation Analysis]
33 Lee D, Baldassano RN, Otley AR, Albenberg L, Griffiths AM, Compher C, Chen EZ, Li H, Gilroy E, Nessel L, Grant A, Chehoud C, Bushman FD, Wu GD, Lewis JD. Comparative Effectiveness of Nutritional and Biological Therapy in North American Children with Active Crohnʼs Disease: . Inflammatory Bowel Diseases 2015;21:1786-93. [DOI: 10.1097/mib.0000000000000426] [Cited by in Crossref: 84] [Cited by in F6Publishing: 34] [Article Influence: 12.0] [Reference Citation Analysis]
34 Alizadeh A, Akbari P, Garssen J, Fink-Gremmels J, Braber S. Epithelial integrity, junctional complexes, and biomarkers associated with intestinal functions. Tissue Barriers 2021;:1996830. [PMID: 34719339 DOI: 10.1080/21688370.2021.1996830] [Reference Citation Analysis]
35 Buisson A, Vazeille E, Minet-Quinard R, Goutte M, Bouvier D, Goutorbe F, Pereira B, Barnich N, Bommelaer G. Fecal Matrix Metalloprotease-9 and Lipocalin-2 as Biomarkers in Detecting Endoscopic Activity in Patients With Inflammatory Bowel Diseases. J Clin Gastroenterol 2018;52:e53-62. [PMID: 28723856 DOI: 10.1097/MCG.0000000000000837] [Cited by in Crossref: 20] [Cited by in F6Publishing: 13] [Article Influence: 6.7] [Reference Citation Analysis]
36 Motaganahalli S, Beswick L, Con D, van Langenberg DR. Faecal calprotectin delivers on convenience, cost reduction and clinical decision-making in inflammatory bowel disease: a real-world cohort study. Intern Med J 2019;49:94-100. [PMID: 29962008 DOI: 10.1111/imj.14027] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
37 Iskandar HN, Ciorba MA. Biomarkers in inflammatory bowel disease: current practices and recent advances. Transl Res. 2012;159:313-325. [PMID: 22424434 DOI: 10.1016/j.trsl.2012.01.001] [Cited by in Crossref: 116] [Cited by in F6Publishing: 106] [Article Influence: 11.6] [Reference Citation Analysis]
38 Cerrillo E, Moret I, Iborra M, Pamies J, Hervás D, Tortosa L, Sáez-gonzález E, Nos P, Beltrán B. A Nomogram Combining Fecal Calprotectin Levels and Plasma Cytokine Profiles for Individual Prediction of Postoperative Crohn’s Disease Recurrence. Inflammatory Bowel Diseases 2019;25:1681-91. [DOI: 10.1093/ibd/izz053] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
39 Rodrigues BL, Mazzaro MC, Nagasako CK, Ayrizono MLS, Fagundes JJ, Leal RF. Assessment of disease activity in inflammatory bowel diseases: Non-invasive biomarkers and endoscopic scores. World J Gastrointest Endosc 2020; 12(12): 504-520 [PMID: 33362904 DOI: 10.4253/wjge.v12.i12.504] [Cited by in CrossRef: 1] [Article Influence: 0.5] [Reference Citation Analysis]
40 Caccaro R, D’Incá R, Sturniolo GC. Clinical utility of calprotectin and lactoferrin as markers of inflammation in patients with inflammatory bowel disease. Expert Rev Clin Immunol. 2010;6:551-558. [PMID: 20594128 DOI: 10.1586/eci.10.26] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
41 Guidi L, Marzo M, Andrisani G, Felice C, Pugliese D, Mocci G, Nardone O, De Vitis I, Papa A, Rapaccini G, Forni F, Armuzzi A. Faecal calprotectin assay after induction with anti-Tumour Necrosis Factor α agents in inflammatory bowel disease: Prediction of clinical response and mucosal healing at one year. Digestive and Liver Disease 2014;46:974-9. [DOI: 10.1016/j.dld.2014.07.013] [Cited by in Crossref: 39] [Cited by in F6Publishing: 37] [Article Influence: 4.9] [Reference Citation Analysis]
42 Gisbert JP, McNicholl AG, Gomollon F. Questions and answers on the role of fecal lactoferrin as a biological marker in inflammatory bowel disease. Inflamm Bowel Dis. 2009;15:1746-1754. [PMID: 19363798 DOI: 10.1002/ibd.20920] [Cited by in Crossref: 65] [Cited by in F6Publishing: 62] [Article Influence: 5.4] [Reference Citation Analysis]
43 Menys A, Makanyanga J, Plumb A, Bhatnagar G, Atkinson D, Emmanuel A, Taylor SA. Aberrant Motility in Unaffected Small Bowel is Linked to Inflammatory Burden and Patient Symptoms in Crohn's Disease. Inflamm Bowel Dis. 2016;22:424-432. [PMID: 26509756 DOI: 10.1097/mib.0000000000000601] [Cited by in Crossref: 14] [Cited by in F6Publishing: 3] [Article Influence: 2.3] [Reference Citation Analysis]
44 Buisson A, Vazeille E, Minet-Quinard R, Goutte M, Bouvier D, Goutorbe F, Pereira B, Barnich N, Bommelaer G. Faecal chitinase 3-like 1 is a reliable marker as accurate as faecal calprotectin in detecting endoscopic activity in adult patients with inflammatory bowel diseases. Aliment Pharmacol Ther. 2016;43:1069-1079. [PMID: 26953251 DOI: 10.1111/apt.13585] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 4.0] [Reference Citation Analysis]
45 Dandin Ö, Akin ML, Balta AZ, Yücel E, Karakaş DÖ, Demirbaş S, Özdemir S, Haholu A. The Efficacy of Probiotic (Lactobacillus rhamnosus GG) and 5-ASA (Aminosalicylic Acid) in the Treatment of Experimental Radiation Proctitis in Rats. Indian J Surg 2015;77:563-9. [PMID: 26730065 DOI: 10.1007/s12262-013-0923-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
46 Dumoulin EN, Van Biervliet S, Delanghe JR. Trypsin is a Potential Confounder in Calprotectin Results. Journal of Pediatric Gastroenterology & Nutrition 2015;61:e19. [DOI: 10.1097/mpg.0000000000000906] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
47 Brookes MJ, Whitehead S, Gaya DR, Hawthorne AB. Practical guidance on the use of faecal calprotectin. Frontline Gastroenterol. 2018;9:87-91. [PMID: 29588834 DOI: 10.1136/flgastro-2016-100762] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 3.6] [Reference Citation Analysis]
48 Inoue K, Aomatsu T, Yoden A, Okuhira T, Kaji E, Tamai H. Usefulness of a novel and rapid assay system for fecal calprotectin in pediatric patients with inflammatory bowel diseases. J Gastroenterol Hepatol. 2014;29:1406-1412. [PMID: 24635100 DOI: 10.1111/jgh.12578] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
49 Lehtola E, Haapamäki J, Färkkilä MA. Outcome of inflammatory bowel disease patients treated with TNF-α inhibitors: two-year follow-up. Scand J Gastroenterol 2016;51:1476-81. [PMID: 27686143 DOI: 10.1080/00365521.2016.1218539] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
50 González-Lama Y, Vera MI, Calvo M, Abreu L. [Markers of the course of inflammatory bowel disease treated with immunomodulators or biological agents]. Gastroenterol Hepatol 2010;33:449-60. [PMID: 20122758 DOI: 10.1016/j.gastrohep.2009.11.005] [Reference Citation Analysis]
51 Langhorst J, Boone J, Lauche R, Rueffer A, Dobos G. Faecal Lactoferrin, Calprotectin, PMN-elastase, CRP, and White Blood Cell Count as Indicators for Mucosal Healing and Clinical Course of Disease in Patients with Mild to Moderate Ulcerative Colitis: Post Hoc Analysis of a Prospective Clinical Trial. J Crohns Colitis 2016;10:786-94. [PMID: 26874351 DOI: 10.1093/ecco-jcc/jjw044] [Cited by in Crossref: 40] [Cited by in F6Publishing: 34] [Article Influence: 6.7] [Reference Citation Analysis]
52 Kim JW, Kim HJ, Lee CK, Shim JJ, Jang JY, Dong SH, Kim BH, Chang YW, Chi SG. Elevation of PRKCDBP, a novel transcriptional target of TNF-α, and its downregulation by infliximab in patients with ulcerative colitis. Dig Dis Sci 2014;59:2947-57. [PMID: 25052149 DOI: 10.1007/s10620-014-3282-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
53 Jensen MD, Kjeldsen J, Nathan T. Fecal calprotectin is equally sensitive in Crohn's disease affecting the small bowel and colon. Scand J Gastroenterol. 2011;46:694-700. [PMID: 21456899 DOI: 10.3109/00365521.2011.560680] [Cited by in Crossref: 58] [Cited by in F6Publishing: 59] [Article Influence: 5.3] [Reference Citation Analysis]
54 Lorenz F, Marklund S, Werner M, Palmqvist R, Wahlin BE, Wahlin A. Fecal calprotectin as a biomarker of intestinal graft versus host disease after allogeneic hematopoietic stem cell transplantation. Sci Rep 2015;5:7920. [PMID: 25605402 DOI: 10.1038/srep07920] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
55 Vernia F, Di Ruscio M, Stefanelli G, Viscido A, Frieri G, Latella G. Is fecal calprotectin an accurate marker in the management of Crohn's disease? J Gastroenterol Hepatol 2020;35:390-400. [PMID: 31795013 DOI: 10.1111/jgh.14950] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
56 Ismail MS, Semenov S, McNamara D. The utility of faecal and urine biomarkers for small bowel diseases. Curr Opin Gastroenterol 2021;37:284-94. [PMID: 33769381 DOI: 10.1097/MOG.0000000000000730] [Reference Citation Analysis]
57 Cintolo M, Costantino G, Pallio S, Fries W. Mucosal healing in inflammatory bowel disease: Maintain or de-escalate therapy. World J Gastrointest Pathophysiol 2016; 7(1): 1-16 [PMID: 26909224 DOI: 10.4291/wjgp.v7.i1.1] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
58 Bertani L, Mumolo MG, Tapete G, Albano E, Baiano Svizzero G, Zanzi F, Ceccarelli L, Bellini M, Marchi S, Costa F. Fecal calprotectin: current and future perspectives for inflammatory bowel disease treatment. Eur J Gastroenterol Hepatol 2020;32:1091-8. [PMID: 32282400 DOI: 10.1097/MEG.0000000000001731] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 12.0] [Reference Citation Analysis]
59 Roblin X, Boschetti G, Duru G, Williet N, Deltedesco E, Phelip JM, Peyrin-Biroulet L, Nancey S, Flourié B, Paul S. Distinct Thresholds of Infliximab Trough Level Are Associated with Different Therapeutic Outcomes in Patients with Inflammatory Bowel Disease: A Prospective Observational Study. Inflamm Bowel Dis 2017;23:2048-53. [PMID: 28945636 DOI: 10.1097/MIB.0000000000001223] [Cited by in Crossref: 24] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
60 Makanyanga JC, Pendsé D, Dikaios N, Bloom S, Mccartney S, Helbren E, Atkins E, Cuthbertson T, Punwani S, Forbes A, Halligan S, Taylor SA. Evaluation of Crohn’s disease activity: Initial validation of a magnetic resonance enterography global score (MEGS) against faecal calprotectin. Eur Radiol 2014;24:277-87. [DOI: 10.1007/s00330-013-3010-z] [Cited by in Crossref: 79] [Cited by in F6Publishing: 70] [Article Influence: 8.8] [Reference Citation Analysis]
61 Garg M, Burrell LM, Velkoska E, Griggs K, Angus PW, Gibson PR, Lubel JS. Upregulation of circulating components of the alternative renin-angiotensin system in inflammatory bowel disease: A pilot study. J Renin Angiotensin Aldosterone Syst 2015;16:559-69. [PMID: 24505094 DOI: 10.1177/1470320314521086] [Cited by in Crossref: 42] [Cited by in F6Publishing: 43] [Article Influence: 5.3] [Reference Citation Analysis]
62 Lewis JD. The utility of biomarkers in the diagnosis and therapy of inflammatory bowel disease. Gastroenterology 2011; 140: 1817-1826. e2. [PMID: 21530748 DOI: 10.1053/j.gastro.2010.11.058] [Cited by in Crossref: 268] [Cited by in F6Publishing: 238] [Article Influence: 24.4] [Reference Citation Analysis]
63 Rufo PA, Denson LA, Sylvester FA, Szigethy E, Sathya P, Lu Y, Wahbeh GT, Sena LM, Faubion WA. Health supervision in the management of children and adolescents with IBD: NASPGHAN recommendations. J Pediatr Gastroenterol Nutr. 2012;55:93-108. [PMID: 22516861 DOI: 10.1097/mpg.0b013e31825959b8] [Cited by in Crossref: 70] [Cited by in F6Publishing: 27] [Article Influence: 7.0] [Reference Citation Analysis]
64 Lobatón T, Rodríguez-moranta F, Lopez A, Sánchez E, Rodríguez-alonso L, Guardiola J. A New Rapid Quantitative Test for Fecal Calprotectin Predicts Endoscopic Activity in Ulcerative Colitis: . Inflammatory Bowel Diseases 2013;19:1034-42. [DOI: 10.1097/mib.0b013e3182802b6e] [Cited by in Crossref: 81] [Cited by in F6Publishing: 29] [Article Influence: 9.0] [Reference Citation Analysis]
65 Mooiweer E, Fidder HH, Siersema PD, Laheij RJ, Oldenburg B. Fecal hemoglobin and calprotectin are equally effective in identifying patients with inflammatory bowel disease with active endoscopic inflammation. Inflamm Bowel Dis. 2014;20:307-314. [PMID: 24374878 DOI: 10.1097/01.mib.0000438428.30800.a6] [Cited by in Crossref: 33] [Cited by in F6Publishing: 18] [Article Influence: 4.7] [Reference Citation Analysis]
66 Shaoul R, Sladek M, Turner D, Paeregaard A, Veres G, Wauters GV, Escher J, Dias JA, Lionetti P, Staino A. Limitations of fecal calprotectin at diagnosis in untreated pediatric Crohn’s disease. Inflamm Bowel Dis. 2012;18:1493-1497. [PMID: 22275268 DOI: 10.1002/ibd.21875] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 2.7] [Reference Citation Analysis]
67 Cordes F, Demmig C, Bokemeyer A, Brückner M, Lenze F, Lenz P, Nowacki T, Tepasse P, Schmidt HH, Schmidt MA, Cichon C, Bettenworth D. MicroRNA-320a Monitors Intestinal Disease Activity in Patients With Inflammatory Bowel Disease.Clin Transl Gastroenterol. 2020;11:e00134. [PMID: 32352717 DOI: 10.14309/ctg.0000000000000134] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
68 Daperno M, Castiglione F, de Ridder L, Dotan I, Färkkilä M, Florholmen J, Fraser G, Fries W, Hebuterne X, Lakatos PL. Results of the 2nd part Scientific Workshop of the ECCO. II: Measures and markers of prediction to achieve, detect, and monitor intestinal healing in inflammatory bowel disease. J Crohns Colitis. 2011;5:484-498. [PMID: 21939926 DOI: 10.1016/j.crohns.2011.07.003] [Cited by in Crossref: 72] [Cited by in F6Publishing: 67] [Article Influence: 6.5] [Reference Citation Analysis]
69 Nogueira IM, Miszputen SJ, Ambrogini Jr. O, Artigiani-neto R, Carvente CT, Zanon MI. ASSESSMENT OF THE RESPONSE OF PATIENTS WITH CROHN'S DISEASE TO BIOLOGICAL THERAPY USING NEW NON-INVASIVE MARKERS: lactoferrin and calprotectin. Arq Gastroenterol 2013;50:130-7. [DOI: 10.1590/s0004-28032013000200022] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
70 Lindholm CR, Siegel CA. Are We Ready to Include Prognostic Factors in Inflammatory Bowel Disease Trials? Curr Pharm Des 2019;25:64-8. [PMID: 30864506 DOI: 10.2174/1381612825666190312113935] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
71 Targownik LE, Bernstein CN, Leslie WD. Inflammatory bowel disease and the risk of osteoporosis and fracture. Maturitas. 2013;76:315-319. [PMID: 24139749 DOI: 10.1016/j.maturitas.2013.09.009] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 2.6] [Reference Citation Analysis]
72 Lopes S, Andrade P, Afonso J, Cunha R, Rodrigues-Pinto E, Ramos I, Macedo G, Magro F. Monitoring Crohn's disease activity: endoscopy, fecal markers and computed tomography enterography. Therap Adv Gastroenterol 2018;11:1756284818769075. [PMID: 29760785 DOI: 10.1177/1756284818769075] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
73 Molander P, Sipponen T, Kemppainen H, Jussila A, Blomster T, Koskela R, Nissinen M, Rautiainen H, Kuisma J, Kolho K, Färkkilä M. Achievement of deep remission during scheduled maintenance therapy with TNFα-blocking agents in IBD. Journal of Crohn's and Colitis 2013;7:730-5. [DOI: 10.1016/j.crohns.2012.10.018] [Cited by in Crossref: 73] [Cited by in F6Publishing: 72] [Article Influence: 8.1] [Reference Citation Analysis]
74 Wright EK, De Cruz P, Gearry R, Day AS, Kamm MA. Fecal biomarkers in the diagnosis and monitoring of Crohn's disease. Inflamm Bowel Dis. 2014;20:1668-1677. [PMID: 24918319 DOI: 10.1097/mib.0000000000000087] [Cited by in Crossref: 38] [Cited by in F6Publishing: 13] [Article Influence: 5.4] [Reference Citation Analysis]
75 Matsuura R, Watanabe O, Nakamura M, Yamamura T, Matsushita M, Suhara H, Furukawa K, Ishikawa T, Funasaka K, Ohno E, Kawashima H, Miyahara R, Hirooka Y, Goto H. Fecal calprotectin reflects endoscopic activity in patients with small-bowel Crohn's disease according to double-balloon endoscopy findings. Nagoya J Med Sci 2018;80:257-66. [PMID: 29915443 DOI: 10.18999/nagjms.80.2.257] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
76 Turkay C, Kasapoglu B. Noninvasive methods in evaluation of inflammatory bowel disease: where do we stand now? An update. Clinics (Sao Paulo). 2010;65:221-231. [PMID: 20186307 DOI: 10.1590/S1807-59322010000200015] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
77 Inokuchi T, Kato J, Hiraoka S, Takashima S, Nakarai A, Takei D, Sugihara Y, Takahara M, Kawano S, Harada K, Okada H. Fecal Immunochemical Test Versus Fecal Calprotectin for Prediction of Mucosal Healing in Crohnʼs Disease: . Inflammatory Bowel Diseases 2016;22:1078-85. [DOI: 10.1097/mib.0000000000000728] [Cited by in Crossref: 30] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
78 Schmidt C, Bachmann O, Baumgart DC, Goetz M, Drvarov O, Kucharzik TF, Kühbacher T, Langhorst J, Maul J, Mohl W, Mudter J, Repp M, Sturm A, Witzemann D, Atreya R. [Position paper on endoscopic reporting in IBD]. Z Gastroenterol 2021. [PMID: 34284522 DOI: 10.1055/a-1504-9782] [Reference Citation Analysis]
79 Halfvarson J, Brislawn CJ, Lamendella R, Vázquez-Baeza Y, Walters WA, Bramer LM, D'Amato M, Bonfiglio F, McDonald D, Gonzalez A, McClure EE, Dunklebarger MF, Knight R, Jansson JK. Dynamics of the human gut microbiome in inflammatory bowel disease. Nat Microbiol 2017;2:17004. [PMID: 28191884 DOI: 10.1038/nmicrobiol.2017.4] [Cited by in Crossref: 452] [Cited by in F6Publishing: 381] [Article Influence: 90.4] [Reference Citation Analysis]
80 Cury DB, Mizsputen SJ, Versolato C, Miiji LO, Pereira E, Delboni MA, Schor N, Moss AC. Serum calprotectin levels correlate with biochemical and histological markers of disease activity in TNBS colitis. Cell Immunol 2013;282:66-70. [PMID: 23685388 DOI: 10.1016/j.cellimm.2013.04.004] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 2.6] [Reference Citation Analysis]
81 Smith LA, Gaya DR. Utility of faecal calprotectin analysis in adult inflammatory bowel disease. World J Gastroenterol 2012; 18(46): 6782-6789 [PMID: 23239916 DOI: 10.3748/wjg.v18.i46.6782] [Cited by in CrossRef: 43] [Cited by in F6Publishing: 31] [Article Influence: 4.3] [Reference Citation Analysis]
82 Kobayashi T, Siegmund B, Le Berre C, Wei SC, Ferrante M, Shen B, Bernstein CN, Danese S, Peyrin-Biroulet L, Hibi T. Ulcerative colitis.Nat Rev Dis Primers. 2020;6:74. [PMID: 32913180 DOI: 10.1038/s41572-020-0205-x] [Cited by in Crossref: 52] [Cited by in F6Publishing: 55] [Article Influence: 26.0] [Reference Citation Analysis]
83 Wright EK, Kamm MA, De Cruz P, Hamilton AL, Ritchie KJ, Keenan JI, Leach S, Burgess L, Aitchison A, Gorelik A. Comparison of Fecal Inflammatory Markers in Crohn's Disease. Inflamm Bowel Dis. 2016;22:1086-1094. [PMID: 26818420 DOI: 10.1097/MIB.0000000000000671] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 2.8] [Reference Citation Analysis]
84 Schaffer T, Schoepfer AM, Seibold F; Swiss IBD Cohort Study Group. Serum ficolin-2 correlates worse than fecal calprotectin and CRP with endoscopic Crohn's disease activity. J Crohns Colitis 2014;8:1125-32. [PMID: 24636141 DOI: 10.1016/j.crohns.2014.02.014] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
85 Monteiro S, Barbosa M, Cúrdia Gonçalves T, Boal Carvalho P, Moreira MJ, Rosa B, Cotter J. Fecal Calprotectin as a Selection Tool for Small Bowel Capsule Endoscopy in Suspected Crohn's Disease. Inflamm Bowel Dis 2018;24:2033-8. [PMID: 29722829 DOI: 10.1093/ibd/izy098] [Cited by in F6Publishing: 11] [Reference Citation Analysis]
86 Laube R, Liu K, Schifter M, Yang JL, Suen MK, Leong RW. Oral and upper gastrointestinal Crohn's disease. J Gastroenterol Hepatol. 2018;33:355-364. [PMID: 28708248 DOI: 10.1111/jgh.13866] [Cited by in Crossref: 26] [Cited by in F6Publishing: 16] [Article Influence: 6.5] [Reference Citation Analysis]
87 Ma C, Battat R, Khanna R, Parker CE, Feagan BG, Jairath V. What is the role of C-reactive protein and fecal calprotectin in evaluating Crohn's disease activity? Best Pract Res Clin Gastroenterol 2019;38-39:101602. [PMID: 31327404 DOI: 10.1016/j.bpg.2019.02.004] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
88 Molander P, Kemppainen H, Ilus T, Sipponen T. Long-term deep remission during maintenance therapy with biological agents in inflammatory bowel diseases. Scand J Gastroenterol 2020;55:34-40. [PMID: 31841064 DOI: 10.1080/00365521.2019.1701070] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
89 Viennois E, Zhao Y, Merlin D. Biomarkers of Inflammatory Bowel Disease: From Classical Laboratory Tools to Personalized Medicine. Inflamm Bowel Dis. 2015;21:2467-2474. [PMID: 25985250 DOI: 10.1097/mib.0000000000000444] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
90 Penna FGC, Rosa RM, Pereira FH, Cunha PFS, Sousa SCS, Ferrari TCA, Cara C, Ferrari MLA. Combined evaluation of fecal calprotectin and C-reactive protein as a therapeutic target in the management of patients with Crohn's disease. Gastroenterol Hepatol 2021;44:87-95. [PMID: 32680729 DOI: 10.1016/j.gastrohep.2020.04.015] [Reference Citation Analysis]
91 Novak G, Parker CE, Pai RK, MacDonald JK, Feagan BG, Sandborn WJ, D'Haens G, Jairath V, Khanna R. Histologic scoring indices for evaluation of disease activity in Crohn's disease. Cochrane Database Syst Rev 2017;7:CD012351. [PMID: 28731502 DOI: 10.1002/14651858.CD012351.pub2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
92 Stawczyk-Eder K, Eder P, Lykowska-Szuber L, Krela-Kazmierczak I, Klimczak K, Szymczak A, Szachta P, Katulska K, Linke K. Is faecal calprotectin equally useful in all Crohn’s disease locations? A prospective, comparative study. Arch Med Sci. 2015;11:353-361. [PMID: 25995752 DOI: 10.5114/aoms.2014.43672] [Cited by in Crossref: 25] [Cited by in F6Publishing: 29] [Article Influence: 3.6] [Reference Citation Analysis]
93 Sherlock ME, Griffiths AM. Medical therapy for pediatric inflammatory bowel disease. Curr Gastroenterol Rep. 2012;14:166-173. [PMID: 22350842 DOI: 10.1007/s11894-012-0249-5] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
94 Sorrentino D, Nguyen VQ, Chitnavis MV. Capturing the Biologic Onset of Inflammatory Bowel Diseases: Impact on Translational and Clinical Science. Cells 2019;8:E548. [PMID: 31174359 DOI: 10.3390/cells8060548] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
95 Nancey S, Boschetti G, Moussata D, Cotte E, Peyras J, Cuerq C, Haybrard J, Charlois AL, Mialon A, Chauvenet M. Neopterin is a novel reliable fecal marker as accurate as calprotectin for predicting endoscopic disease activity in patients with inflammatory bowel diseases. Inflamm Bowel Dis. 2013;19:1043-1052. [PMID: 23511035 DOI: 10.1097/mib.0b013e3182807577] [Cited by in Crossref: 69] [Cited by in F6Publishing: 29] [Article Influence: 7.7] [Reference Citation Analysis]
96 Benítez JM, García-Sánchez V. Faecal calprotectin: Management in inflammatory bowel disease. World J Gastrointest Pathophysiol 2015; 6(4): 203-209 [PMID: 26600978 DOI: 10.4291/wjgp.v6.i4.203] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
97 Khanna R, Nelson SA, Feagan BG, D'Haens G, Sandborn WJ, Zou GY, MacDonald JK, Parker CE, Jairath V, Levesque BG. Endoscopic scoring indices for evaluation of disease activity in Crohn's disease. Cochrane Database Syst Rev 2016;:CD010642. [PMID: 27501379 DOI: 10.1002/14651858.CD010642.pub2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
98 Shimoyama T, Yamamoto T, Umegae S, Matsumoto K. Faecal biomarkers for screening small bowel inflammation in patients with Crohn's disease: a prospective study. Therap Adv Gastroenterol 2017;10:577-87. [PMID: 28835772 DOI: 10.1177/1756283X17717683] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
99 Sipponen T, Kolho KL. Fecal calprotectin in diagnosis and clinical assessment of inflammatory bowel disease. Scand J Gastroenterol. 2015;50:74-80. [PMID: 25523558 DOI: 10.3109/00365521.2014.987809] [Cited by in Crossref: 66] [Cited by in F6Publishing: 59] [Article Influence: 9.4] [Reference Citation Analysis]
100 D'Amico F, Bonovas S, Danese S, Peyrin-Biroulet L. Review article: faecal calprotectin and histologic remission in ulcerative colitis.Aliment Pharmacol Ther. 2020;51:689-698. [PMID: 32048751 DOI: 10.1111/apt.15662] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 11.0] [Reference Citation Analysis]
101 E Penna FGC, Rosa RM, da Cunha PFS, de Souza SCS, de Abreu Ferrari ML. Faecal calprotectin is the biomarker that best distinguishes remission from different degrees of endoscopic activity in Crohn's disease. BMC Gastroenterol. 2020;20:35. [PMID: 32054445 DOI: 10.1186/s12876-020-1183-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
102 Goutorbe F, Goutte M, Minet-Quinard R, Boucher AL, Pereira B, Bommelaer G, Buisson A. Endoscopic Factors Influencing Fecal Calprotectin Value in Crohn's Disease. J Crohns Colitis. 2015;9:1113-1119. [PMID: 26351383 DOI: 10.1093/ecco-jcc/jjv150] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 3.6] [Reference Citation Analysis]
103 Papay P, Ignjatovic A, Karmiris K, Amarante H, Miheller P, Feagan B, D'haens G, Marteau P, Reinisch W, Sturm A, Steinwurz F, Egan L, Panés J, Louis E, Colombel J, Panaccione R. Optimising monitoring in the management of Crohn's disease: A physician's perspective. Journal of Crohn's and Colitis 2013;7:653-69. [DOI: 10.1016/j.crohns.2013.02.005] [Cited by in Crossref: 69] [Cited by in F6Publishing: 61] [Article Influence: 7.7] [Reference Citation Analysis]
104 Beardslee LA, Banis GE, Chu S, Liu S, Chapin AA, Stine JM, Pasricha PJ, Ghodssi R. Ingestible Sensors and Sensing Systems for Minimally Invasive Diagnosis and Monitoring: The Next Frontier in Minimally Invasive Screening. ACS Sens 2020;5:891-910. [DOI: 10.1021/acssensors.9b02263] [Cited by in Crossref: 23] [Cited by in F6Publishing: 14] [Article Influence: 11.5] [Reference Citation Analysis]
105 Malham M, Carlsen K, Riis L, Paerregaard A, Vind I, Fenger M, Wewer V. Plasma calprotectin is superior to serum calprotectin as a biomarker of intestinal inflammation in ulcerative Colitis. Scand J Gastroenterol 2019;54:1214-9. [PMID: 31526273 DOI: 10.1080/00365521.2019.1665097] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
106 Shen EX, Lord A, Doecke JD, Hanigan K, Irwin J, Cheng RK, Radford-smith G. A validated risk stratification tool for detecting high-risk small bowel Crohn's disease. Aliment Pharmacol Ther 2020;51:281-90. [DOI: 10.1111/apt.15550] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
107 Koutroumpakis E, Katsanos KH. Implementation of the simple endoscopic activity score in crohn's disease. Saudi J Gastroenterol 2016;22:183-91. [PMID: 27184635 DOI: 10.4103/1319-3767.182455] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 3.4] [Reference Citation Analysis]
108 Moscandrew ME, Loftus EV. Diagnostic advances in inflammatory bowel disease (imaging and laboratory). Curr Gastroenterol Rep 2009;11:488-95. [DOI: 10.1007/s11894-009-0074-7] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.1] [Reference Citation Analysis]
109 Pai RK, Geboes K. Disease activity and mucosal healing in inflammatory bowel disease: a new role for histopathology? Virchows Arch. 2018;472:99-110. [PMID: 28555281 DOI: 10.1007/s00428-017-2156-5] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 3.8] [Reference Citation Analysis]
110 Buisson A, Gonzalez F, Poullenot F, Nancey S, Sollellis E, Fumery M, Pariente B, Flamant M, Trang-Poisson C, Bonnaud G. Comparative Acceptability and Perceived Clinical Utility of Monitoring Tools: A Nationwide Survey of Patients with Inflammatory Bowel Disease. Inflamm Bowel Dis. 2017;23:1425-1433. [PMID: 28570431 DOI: 10.1097/mib.0000000000001140] [Cited by in Crossref: 66] [Cited by in F6Publishing: 20] [Article Influence: 16.5] [Reference Citation Analysis]
111 Arai T, Takeuchi K, Miyamura M, Ishikawa R, Yamada A, Katsumata M, Igarashi Y, Suzuki Y. Level of Fecal Calprotectin Correlates With Severity of Small Bowel Crohn’s Disease, Measured by Balloon-assisted Enteroscopy and Computed Tomography Enterography. Clinical Gastroenterology and Hepatology 2017;15:56-62. [DOI: 10.1016/j.cgh.2016.08.015] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 5.6] [Reference Citation Analysis]
112 Lobatón T, López-garcía A, Rodríguez-moranta F, Ruiz A, Rodríguez L, Guardiola J. A new rapid test for fecal calprotectin predicts endoscopic remission and postoperative recurrence in Crohn's disease. Journal of Crohn's and Colitis 2013;7:e641-51. [DOI: 10.1016/j.crohns.2013.05.005] [Cited by in Crossref: 102] [Cited by in F6Publishing: 96] [Article Influence: 11.3] [Reference Citation Analysis]
113 Gong W, Guo K, Zheng T, Fang M, Xie H, Li W, Hong Z, Ren H, Gu G, Wang G, Wu X, Wang Z, Ren J, Li J. Correlation between endoscopic and histological validated scoring indices in Crohn’s disease. Digestive and Liver Disease 2019;51:812-7. [DOI: 10.1016/j.dld.2019.01.010] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
114 Pabla BS, Schwartz DA. Assessing Severity of Disease in Patients with Ulcerative Colitis. Gastroenterol Clin North Am 2020;49:671-88. [PMID: 33121688 DOI: 10.1016/j.gtc.2020.08.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
115 Sidoroff M, Karikoski R, Raivio T, Savilahti E, Kolho KL. High-sensitivity C-reactive protein in paediatric inflammatory bowel disease. World J Gastroenterol 2010; 16(23): 2901-2906 [PMID: 20556836 DOI: 10.3748/wjg.v16.i23.2901] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 23] [Article Influence: 1.8] [Reference Citation Analysis]
116 Puolanne AM, Kolho KL, Alfthan H, Ristimäki A, Mustonen H, Färkkilä M. Rapid faecal tests for detecting disease activity in colonic inflammatory bowel disease. Eur J Clin Invest 2016;46:825-32. [PMID: 27438629 DOI: 10.1111/eci.12660] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
117 van Rheenen PF, Van de Vijver E, Fidler V. Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic meta-analysis. BMJ 2010;341:c3369. [PMID: 20634346 DOI: 10.1136/bmj.c3369] [Cited by in Crossref: 392] [Cited by in F6Publishing: 351] [Article Influence: 32.7] [Reference Citation Analysis]
118 Boon GJ, Day AS, Mulder CJ, Gearry RB. Are faecal markers good indicators of mucosal healing in inflammatory bowel disease? World J Gastroenterol 2015; 21(40): 11469-11480 [PMID: 26523111 DOI: 10.3748/wjg.v21.i40.11469] [Cited by in CrossRef: 35] [Cited by in F6Publishing: 34] [Article Influence: 5.0] [Reference Citation Analysis]
119 Mak LY, Tong TSM, Cheung KS, Chen LJ, Lui KL, Lau KS, Leung WK. Combined Use of Common Fecal and Blood Markers for Detection of Endoscopically Active Inflammatory Bowel Disease. Clin Transl Gastroenterol. 2020;11:e00138. [PMID: 32132451 DOI: 10.14309/ctg.0000000000000138] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
120 D'Angelo F, Felley C, Frossard JL. Calprotectin in Daily Practice: Where Do We Stand in 2017? Digestion 2017;95:293-301. [PMID: 28511188 DOI: 10.1159/000476062] [Cited by in Crossref: 26] [Cited by in F6Publishing: 20] [Article Influence: 5.2] [Reference Citation Analysis]
121 Dhaliwal A, Zeino Z, Tomkins C, Cheung M, Nwokolo C, Smith S, Harmston C, Arasaradnam RP. Utility of faecal calprotectin in inflammatory bowel disease (IBD): what cut-offs should we apply? Frontline Gastroenterol. 2015;6:14-19. [PMID: 25580205 DOI: 10.1136/flgastro-2013-100420] [Cited by in Crossref: 55] [Cited by in F6Publishing: 50] [Article Influence: 6.9] [Reference Citation Analysis]
122 Mooiweer E, Severs M, Schipper ME, Fidder HH, Siersema PD, Laheij RJ, Oldenburg B. Low fecal calprotectin predicts sustained clinical remission in inflammatory bowel disease patients: a plea for deep remission. J Crohns Colitis. 2015;9:50-55. [PMID: 25518048 DOI: 10.1093/ecco-jcc/jju003] [Cited by in Crossref: 80] [Cited by in F6Publishing: 69] [Article Influence: 10.0] [Reference Citation Analysis]
123 Reenaers C, Bossuyt P, Hindryckx P, Vanpoucke H, Cremer A, Baert F. Expert opinion for use of faecal calprotectin in diagnosis and monitoring of inflammatory bowel disease in daily clinical practice. United European Gastroenterol J 2018;6:1117-25. [PMID: 30288273 DOI: 10.1177/2050640618784046] [Cited by in Crossref: 29] [Cited by in F6Publishing: 22] [Article Influence: 7.3] [Reference Citation Analysis]
124 Schoepfer AM, Beglinger C, Straumann A, Trummler M, Vavricka SR, Bruegger LE, Seibold F. Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn's disease (SES-CD) than CRP, blood leukocytes, and the CDAI. Am J Gastroenterol. 2010;105:162-169. [PMID: 19755969 DOI: 10.1038/ajg.2009.545] [Cited by in Crossref: 344] [Cited by in F6Publishing: 317] [Article Influence: 26.5] [Reference Citation Analysis]
125 Aomatsu T, Yoden A, Matsumoto K, Kimura E, Inoue K, Andoh A, Tamai H. Fecal calprotectin is a useful marker for disease activity in pediatric patients with inflammatory bowel disease. Dig Dis Sci. 2011;56:2372-2377. [PMID: 21394462 DOI: 10.1007/s10620-011-1633-y] [Cited by in Crossref: 68] [Cited by in F6Publishing: 59] [Article Influence: 6.2] [Reference Citation Analysis]
126 Tursi A, Elisei W, Picchio M, Giorgetti G, Brandimarte G. Accuracy of Rapid Fecal Calprotectin Test in Monitoring Inflammatory Bowel Diseases Under Treatment with TNFα Antagonists. Dig Dis Sci 2015;60:1406-13. [PMID: 25445163 DOI: 10.1007/s10620-014-3459-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
127 Pai RK, Jairath V. What is the role of histopathology in the evaluation of disease activity in Crohn's disease? Best Pract Res Clin Gastroenterol 2019;38-39:101601. [PMID: 31327406 DOI: 10.1016/j.bpg.2019.02.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
128 Rogler G, Vavricka S, Schoepfer A, Lakatos PL. Mucosal healing and deep remission: What does it mean? World J Gastroenterol 2013; 19(43): 7552-7560 [PMID: 24282345 DOI: 10.3748/wjg.v19.i43.7552] [Cited by in CrossRef: 42] [Cited by in F6Publishing: 40] [Article Influence: 4.7] [Reference Citation Analysis]
129 Buisson A, Mak WY, Andersen MJ, Lei D, Kahn SA, Pekow J, Cohen RD, Zmeter N, Pereira B, Rubin DT. Faecal Calprotectin Is a Very Reliable Tool to Predict and Monitor the Risk of Relapse After Therapeutic De-escalation in Patients With Inflammatory Bowel Diseases. J Crohns Colitis. 2019;13:1012-1024. [PMID: 30726887 DOI: 10.1093/ecco-jcc/jjz023] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 7.0] [Reference Citation Analysis]
130 Kopylov U, Rosenfeld G, Bressler B, Seidman E. Clinical utility of fecal biomarkers for the diagnosis and management of inflammatory bowel disease. Inflamm Bowel Dis. 2014;20:742-756. [PMID: 24562174 DOI: 10.1097/01.mib.0000442681.85545.31] [Cited by in Crossref: 99] [Cited by in F6Publishing: 37] [Article Influence: 14.1] [Reference Citation Analysis]
131 Yamamoto T, Bamba T, Umegae S, Matsumoto K. The impact of early endoscopic lesions on the clinical course of patients following ileocolonic resection for Crohn's disease: A 5-year prospective cohort study. United European Gastroenterol J 2013;1:294-8. [PMID: 24917974 DOI: 10.1177/2050640613495197] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
132 Zhang H, Zeng Z, Mukherjee A, Shen B. Molecular diagnosis and classification of inflammatory bowel disease. Expert Rev Mol Diagn. 2018;18:867-886. [PMID: 30152711 DOI: 10.1080/14737159.2018.1516549] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
133 McFarlane M, Chambers S, Malik A, Lee B, Sung E, Nwokolo C, Waugh N, Arasaradnam R. Clinical outcomes at 12 months and risk of inflammatory bowel disease in patients with an intermediate raised fecal calprotectin: a 'real-world' view. BMJ Open 2016;6:e011041. [PMID: 27266773 DOI: 10.1136/bmjopen-2016-011041] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
134 De Cruz P, Kamm MA, Prideaux L, Allen PB, Moore G. Mucosal Healing in Crohnʼs Disease: A Systematic Review. Inflammatory Bowel Diseases 2013;19:429-44. [DOI: 10.1002/ibd.22977] [Cited by in Crossref: 101] [Cited by in F6Publishing: 88] [Article Influence: 11.2] [Reference Citation Analysis]
135 Morris MW, Stewart SA, Heisler C, Sandborn WJ, Loftus EV, Zello GA, Fowler SA, Jones JL. Biomarker-Based Models Outperform Patient-Reported Scores in Predicting Endoscopic Inflammatory Disease Activity. Inflamm Bowel Dis 2018;24:277-85. [PMID: 29361090 DOI: 10.1093/ibd/izx018] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
136 Van Biervliet S, Declercq D, Somerset S. Clinical effects of probiotics in cystic fibrosis patients: A systematic review. Clin Nutr ESPEN 2017;18:37-43. [PMID: 29132736 DOI: 10.1016/j.clnesp.2017.01.007] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 3.6] [Reference Citation Analysis]
137 Pendsé DA, Makanyanga JC, Plumb AA, Bhatnagar G, Atkinson D, Rodriguez-Justo M, Halligan S, Taylor SA. Diffusion-weighted imaging for evaluating inflammatory activity in Crohn's disease: comparison with histopathology, conventional MRI activity scores, and faecal calprotectin. Abdom Radiol (NY) 2017;42:115-23. [PMID: 27567607 DOI: 10.1007/s00261-016-0863-z] [Cited by in F6Publishing: 24] [Reference Citation Analysis]
138 Adedokun OJ, Xu Z, Marano C, O’brien C, Szapary P, Zhang H, Johanns J, Leong RW, Hisamatsu T, Van Assche G, Danese S, Abreu MT, Sands BE, Sandborn WJ. Ustekinumab Pharmacokinetics and Exposure Response in a Phase 3 Randomized Trial of Patients With Ulcerative Colitis. Clinical Gastroenterology and Hepatology 2020;18:2244-2255.e9. [DOI: 10.1016/j.cgh.2019.11.059] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 9.5] [Reference Citation Analysis]
139 Zhulina Y, Cao Y, Amcoff K, Carlson M, Tysk C, Halfvarson J. The prognostic significance of faecal calprotectin in patients with inactive inflammatory bowel disease. Aliment Pharmacol Ther. 2016;44:495-504. [PMID: 27402063 DOI: 10.1111/apt.13731] [Cited by in Crossref: 35] [Cited by in F6Publishing: 31] [Article Influence: 5.8] [Reference Citation Analysis]
140 Aalto K, Lahdenne P, Kolho KL. Fecal calprotectin in juvenile idiopathic arthritis patients related to drug use. Pediatr Rheumatol Online J 2017;15:9. [PMID: 28143478 DOI: 10.1186/s12969-016-0132-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
141 Sorrentino D. Preclinical and Undiagnosed Crohnʼs Disease: The Submerged Iceberg. Inflammatory Bowel Diseases 2016;22:476-86. [DOI: 10.1097/mib.0000000000000612] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
142 Lin X, Qiu Y, Feng R, Chen B, He Y, Zeng Z, Zhang S, Chen M, Mao R. Normalization of C-Reactive Protein Predicts Better Outcome in Patients With Crohn's Disease With Mucosal Healing and Deep Remission. Clin Transl Gastroenterol 2020;11:e00135. [PMID: 32463625 DOI: 10.14309/ctg.0000000000000135] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
143 Pavlidis P, Gulati S, Dubois P, Chung-faye G, Sherwood R, Bjarnason I, Hayee B. Early change in faecal calprotectin predicts primary non-response to anti-TNFα therapy in Crohn’s disease. Scandinavian Journal of Gastroenterology 2016;51:1447-52. [DOI: 10.1080/00365521.2016.1205128] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
144 Fu Y, Wang L, Xie C, Zou K, Tu L, Yan W, Hou X. Comparison of non-invasive biomarkers faecal BAFF, calprotectin and FOBT in discriminating IBS from IBD and evaluation of intestinal inflammation. Sci Rep. 2017;7:2669. [PMID: 28572616 DOI: 10.1038/s41598-017-02835-5] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 3.8] [Reference Citation Analysis]
145 Yu Y, Zhao H, Luo Y, Lou J, Chen J, Fang Y. Poor Concordance Between Clinical Activity and Endoscopic Severity in Pediatric Crohn's Disease: Before and After Induction Therapy. Dig Dis Sci. 2021;. [PMID: 33818661 DOI: 10.1007/s10620-021-06917-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
146 Ma C, Battat R, Parker CE, Khanna R, Jairath V, Feagan BG. Update on C-reactive protein and fecal calprotectin: are they accurate measures of disease activity in Crohn’s disease? Expert Review of Gastroenterology & Hepatology 2019;13:319-30. [DOI: 10.1080/17474124.2019.1563481] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
147 Molander P, Färkkilä M, Ristimäki A, Salminen K, Kemppainen H, Blomster T, Koskela R, Jussila A, Rautiainen H, Nissinen M, Haapamäki J, Arkkila P, Nieminen U, Kuisma J, Punkkinen J, Kolho K, Mustonen H, Sipponen T. Does fecal calprotectin predict short-term relapse after stopping TNFα-blocking agents in inflammatory bowel disease patients in deep remission? Journal of Crohn's and Colitis 2014. [DOI: 10.1016/j.crohns.2014.06.012] [Cited by in Crossref: 15] [Cited by in F6Publishing: 38] [Article Influence: 1.9] [Reference Citation Analysis]
148 Cordes F, Brückner M, Lenz P, Veltman K, Glauben R, Siegmund B, Hengst K, Schmidt MA, Cichon C, Bettenworth D. MicroRNA-320a Strengthens Intestinal Barrier Function and Follows the Course of Experimental Colitis: . Inflammatory Bowel Diseases 2016;22:2341-55. [DOI: 10.1097/mib.0000000000000917] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 2.2] [Reference Citation Analysis]
149 Puolanne A, Kolho K, Alfthan H, Ristimäki A, Mustonen H, Färkkilä M. Rapid Fecal Calprotectin Test and Symptom Index in Monitoring the Disease Activity in Colonic Inflammatory Bowel Disease. Dig Dis Sci 2017;62:3123-30. [DOI: 10.1007/s10620-017-4770-0] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.6] [Reference Citation Analysis]
150 Rodríguez-moranta F, Lobatón T, Rodríguez-alonso L, Guardiola J. Calprotectina fecal en el diagnóstico de enfermedades inflamatorias. Gastroenterología y Hepatología 2013;36:400-6. [DOI: 10.1016/j.gastrohep.2012.10.008] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 0.9] [Reference Citation Analysis]
151 Bjarnason I, Hayee B, Pavlidis P, Kvasnovsky C, Scalori A, Sisson G, Charlesworth A, Shaikh H, Bjornsson E, Heneghan MA. Contrasting Pattern of Chronic Inflammatory Bowel Disease in Primary and Autoimmune Sclerosing Cholangitis. EBioMedicine 2015;2:1523-7. [PMID: 26629548 DOI: 10.1016/j.ebiom.2015.08.041] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 1.9] [Reference Citation Analysis]
152 Yamamoto T, Kotze PG. Is fecal calprotectin useful for monitoring endoscopic disease activity in patients with postoperative Crohn's disease? J Crohns Colitis 2013;7:e712. [PMID: 23999186 DOI: 10.1016/j.crohns.2013.08.005] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
153 Seibold F, Schoepfer AM. Can fecal calprotectin or lactoferrin identify postoperative recurrence in Crohn's disease? Inflamm Bowel Dis 2010;16:1814-5. [PMID: 19998454 DOI: 10.1002/ibd.21173] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
154 Toedter GP, Blank M, Lang Y, Chen D, Sandborn WJ, de Villiers WJ. Relationship of C-reactive protein with clinical response after therapy with ustekinumab in Crohn's disease. Am J Gastroenterol. 2009;104:2768-2773. [PMID: 19672253 DOI: 10.1038/ajg.2009.454] [Cited by in Crossref: 49] [Cited by in F6Publishing: 43] [Article Influence: 3.8] [Reference Citation Analysis]
155 Chew TS, Mansfield JC. Can faecal calprotectin predict relapse in inflammatory bowel disease: A mini review. Frontline Gastroenterol. 2018;9:23-28. [PMID: 29484157 DOI: 10.1136/flgastro-2016-100686] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
156 Gecse KB, Brandse JF, van Wilpe S, Löwenberg M, Ponsioen C, van den Brink G, D’Haens G. Impact of disease location on fecal calprotectin levels in Crohn’s disease. Scand J Gastroenterol. 2015;50:841-847. [PMID: 25636819 DOI: 10.3109/00365521.2015.1008035] [Cited by in Crossref: 64] [Cited by in F6Publishing: 57] [Article Influence: 9.1] [Reference Citation Analysis]
157 Pierre N, Salée C, Vieujean S, Bequet E, Merli AM, Siegmund B, Meuwis MA, Louis E. Review article: distinctions between ileal and colonic Crohn's disease: from physiology to pathology. Aliment Pharmacol Ther 2021;54:779-91. [PMID: 34297423 DOI: 10.1111/apt.16536] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
158 Radillo O, Pascolo L, Martelossi S, Dal Bo S, Ventura A. Fecal Calprotectin: Diagnostic Accuracy of the Immunochromatographic CalFast Assay in a Pediatric Population. J Clin Lab Anal 2016;30:500-5. [PMID: 26879689 DOI: 10.1002/jcla.21886] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
159 Bouguen G, Levesque BG, Feagan BG, Kavanaugh A, Peyrin–biroulet L, Colombel J, Hanauer SB, Sandborn WJ. Treat to Target: A Proposed New Paradigm for the Management of Crohn's Disease. Clinical Gastroenterology and Hepatology 2015;13:1042-1050.e2. [DOI: 10.1016/j.cgh.2013.09.006] [Cited by in Crossref: 163] [Cited by in F6Publishing: 143] [Article Influence: 23.3] [Reference Citation Analysis]
160 Crighton A. Paediatric gastrointestinal conditions and their oral implications. Int J Paediatr Dent 2013;23:338-45. [PMID: 23947420 DOI: 10.1111/ipd.12056] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
161 Sipponen T, Haapamäki J, Savilahti E, Alfthan H, Hämäläinen E, Rautiainen H, Koskenpato J, Nuutinen H, Färkkilä M. Fecal calprotectin and S100A12 have low utility in prediction of small bowel Crohn’s disease detected by wireless capsule endoscopy. Scand J Gastroenterol. 2012;47:778-784. [PMID: 22519419 DOI: 10.3109/00365521.2012.677953] [Cited by in Crossref: 49] [Cited by in F6Publishing: 46] [Article Influence: 4.9] [Reference Citation Analysis]
162 Yamamoto T, Shiraki M, Bamba T, Umegae S, Matsumoto K. Faecal calprotectin and lactoferrin as markers for monitoring disease activity and predicting clinical recurrence in patients with Crohn’s disease after ileocolonic resection: A prospective pilot study. United European Gastroenterol J. 2013;1:368-374. [PMID: 24917985 DOI: 10.1177/2050640613501818] [Cited by in Crossref: 46] [Cited by in F6Publishing: 46] [Article Influence: 5.8] [Reference Citation Analysis]
163 Berrill JW, Green JT, Hood K, Campbell AK. Symptoms of irritable bowel syndrome in patients with inflammatory bowel disease: examining the role of sub-clinical inflammation and the impact on clinical assessment of disease activity. Aliment Pharmacol Ther. 2013;38:44-51. [PMID: 23668698 DOI: 10.1111/apt.12335] [Cited by in Crossref: 63] [Cited by in F6Publishing: 65] [Article Influence: 7.0] [Reference Citation Analysis]
164 Jung YS, Park JJ, Kim SW, Hong SP, Kim TI, Kim WH, Cheon JH. Correlation between soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) expression and endoscopic activity in inflammatory bowel diseases. Dig Liver Dis 2012;44:897-903. [PMID: 22721842 DOI: 10.1016/j.dld.2012.05.011] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
165 D’Incà R, Caccaro R. Measuring disease activity in Crohn’s disease: what is currently available to the clinician. Clin Exp Gastroenterol. 2014;7:151-161. [PMID: 24876789 DOI: 10.2147/ceg.s41413] [Cited by in Crossref: 39] [Cited by in F6Publishing: 23] [Article Influence: 4.9] [Reference Citation Analysis]
166 Pous-serrano S, Frasson M, Cerrillo E, Beltrán B, Iborra M, Hervás D, García-granero E, Nos P. Correlation between fecal calprotectin and inflammation in the surgical specimen of Crohn's disease. Journal of Surgical Research 2017;213:290-7. [DOI: 10.1016/j.jss.2017.02.064] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
167 Yzet C, Diouf M, Le Mouel JP, Brazier F, Turpin J, Loreau J, Dupas JL, Peyrin-Biroulet L, Fumery M. Complete Endoscopic Healing Associated With Better Outcomes Than Partial Endoscopic Healing in Patients With Crohn's Disease. Clin Gastroenterol Hepatol 2020;18:2256-61. [PMID: 31743755 DOI: 10.1016/j.cgh.2019.11.025] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
168 Malgras B, Pautrat K, Dray X, Pasquier P, Valleur P, Pocard M, Soyer P. Multidisciplinary Management of Gastrointestinal Fibrotic Stenosis in Crohn’s Disease. Dig Dis Sci 2015;60:1152-68. [DOI: 10.1007/s10620-014-3421-y] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
169 Ma C, Lumb R, Walker EV, Foshaug RR, Dang TT, Verma S, Huang VW, Kroeker KI, Wong K, Dieleman LA, Fedorak RN, Halloran BP. Noninvasive Fecal Immunochemical Testing and Fecal Calprotectin Predict Mucosal Healing in Inflammatory Bowel Disease: A Prospective Cohort Study. Inflammatory Bowel Diseases 2017;23:1643-9. [DOI: 10.1097/mib.0000000000001173] [Cited by in Crossref: 26] [Cited by in F6Publishing: 8] [Article Influence: 5.2] [Reference Citation Analysis]
170 Liu F, Lee SA, Riordan SM, Zhang L, Zhu L. Global Studies of Using Fecal Biomarkers in Predicting Relapse in Inflammatory Bowel Disease. Front Med (Lausanne) 2020;7:580803. [PMID: 33392214 DOI: 10.3389/fmed.2020.580803] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
171 Labaere D, Smismans A, Van Olmen A, Christiaens P, D'Haens G, Moons V, Cuyle PJ, Frans J, Bossuyt P. Comparison of six different calprotectin assays for the assessment of inflammatory bowel disease. United European Gastroenterol J. 2014;2:30-37. [PMID: 24918006 DOI: 10.1177/2050640613518201] [Cited by in Crossref: 82] [Cited by in F6Publishing: 81] [Article Influence: 10.3] [Reference Citation Analysis]
172 Selinger CP, Nelson-Piercy C, Fraser A, Hall V, Limdi J, Smith L, Smith M, Nasur R, Gunn M, King A, Mohan A, Mulgabal K, Kent A, Kok KB, Glanville T. IBD in pregnancy: recent advances, practical management. Frontline Gastroenterol 2021;12:214-24. [PMID: 33912333 DOI: 10.1136/flgastro-2019-101371] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
173 Ha C, Kornbluth A. Mucosal healing in inflammatory bowel disease: where do we stand? Curr Gastroenterol Rep. 2010;12:471-478. [PMID: 20886319 DOI: 10.1007/s11894-010-0146-8] [Cited by in Crossref: 31] [Cited by in F6Publishing: 33] [Article Influence: 2.8] [Reference Citation Analysis]
174 Yang DH, Yang SK, Park SH, Lee HS, Boo SJ, Park JH, Na SY, Jung KW, Kim KJ, Ye BD, Byeon JS, Myung SJ. Usefulness of C-reactive protein as a disease activity marker in Crohn's disease according to the location of disease. Gut Liver 2015;9:80-6. [PMID: 25170056 DOI: 10.5009/gnl13424] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 3.4] [Reference Citation Analysis]
175 Barbosa JA, Rodrigues LA, Columbus DA, Aguirre JCP, Harding JCS, Cantarelli VS, Costa MO. Experimental infectious challenge in pigs leads to elevated fecal calprotectin levels following colitis, but not enteritis. Porcine Health Manag 2021;7:48. [PMID: 34429170 DOI: 10.1186/s40813-021-00228-9] [Reference Citation Analysis]
176 Yamamoto T, Shiraki M, Bamba T, Umegae S, Matsumoto K. Fecal calprotectin and lactoferrin as predictors of relapse in patients with quiescent ulcerative colitis during maintenance therapy. Int J Colorectal Dis. 2014;29:485-491. [PMID: 24343276 DOI: 10.1007/s00384-013-1817-3] [Cited by in Crossref: 47] [Cited by in F6Publishing: 46] [Article Influence: 5.2] [Reference Citation Analysis]
177 Lee JM, Jang JH, Ryu JH, Yoo J, Lee BI, Kim SJ, Oh EJ. A comparison of diagnostic performance between two quantitative rapid fecal calprotectin assays in detecting active inflammatory bowel disease. PLoS One 2021;16:e0255974. [PMID: 34383847 DOI: 10.1371/journal.pone.0255974] [Reference Citation Analysis]
178 Walker GJ, Moore L, Heerasing N, Hendy P, Perry MH, Mcdonald TJ, Debenham T, Bethune R, Bewshea C, Hyde C, Heap GA, Singh A, Calvert C, Kennedy NA, Goodhand JR, Ahmad T. Faecal calprotectin effectively excludes inflammatory bowel disease in 789 symptomatic young adults with/without alarm symptoms: a prospective UK primary care cohort study. Aliment Pharmacol Ther 2018;47:1103-16. [DOI: 10.1111/apt.14563] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 4.8] [Reference Citation Analysis]
179 Carlsen A, Omdal R, Karlsen L, Kvaløy JT, Aabakken L, Steinsbø Ø, Bolstad N, Warren D, Lundin KEA, Grimstad T. Determination of lower cut-off levels of adalimumab associated with biochemical remission in Crohn's disease. JGH Open 2020;4:410-6. [PMID: 32514446 DOI: 10.1002/jgh3.12266] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
180 Fukunaga S, Kuwaki K, Mitsuyama K, Takedatsu H, Yoshioka S, Yamasaki H, Yamauchi R, Mori A, Kakuma T, Tsuruta O, Torimura T. Detection of calprotectin in inflammatory bowel disease: Fecal and serum levels and immunohistochemical localization. Int J Mol Med 2018;41:107-18. [PMID: 29115397 DOI: 10.3892/ijmm.2017.3244] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
181 Cummins G, Yung DE, Cox BF, Koulaouzidis A, Desmulliez MPY, Cochran S. Luminally expressed gastrointestinal biomarkers. Expert Review of Gastroenterology & Hepatology 2017;11:1119-34. [DOI: 10.1080/17474124.2017.1373017] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
182 Ministro P, Martins D. Fecal biomarkers in inflammatory bowel disease: how, when and why? Expert Rev Gastroenterol Hepatol 2017;11:317-28. [PMID: 28276813 DOI: 10.1080/17474124.2017.1292128] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
183 Du L, Foshaug R, Huang VW, Kroeker KI, Dieleman LA, Halloran BP, Wong K, Fedorak RN. Within-Stool and Within-Day Sample Variability of Fecal Calprotectin in Patients With Inflammatory Bowel Disease: A Prospective Observational Study. Journal of Clinical Gastroenterology 2018;52:235-40. [DOI: 10.1097/mcg.0000000000000776] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 3.3] [Reference Citation Analysis]
184 Kennedy NA, Jones GR, Plevris N, Patenden R, Arnott ID, Lees CW. Association Between Level of Fecal Calprotectin and Progression of Crohn's Disease. Clin Gastroenterol Hepatol. 2019;17:2269-2276. [PMID: 30772585 DOI: 10.1016/j.cgh.2019.02.017] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 7.7] [Reference Citation Analysis]
185 Li BR, Sun T, Li J, Li M, Ning SB, Jin XW, Zhu M, Mao GP. Predictors for Small Bowel Stenosis in Balloon-Assisted Enteroscopy. Dig Dis Sci 2020;65:2630-6. [PMID: 31894488 DOI: 10.1007/s10620-019-05990-z] [Reference Citation Analysis]
186 Jeong Y, Jeon SR, Kim HG, Moon JR, Lee TH, Jang JY, Cho JH, Park JS, Park H, Lee KH, Kim JO, Lee JS, Ko BM, Park S. The role of platelet to lymphocyte ratio and neutrophil to lymphocyte ratio in ulcerative colitis. Intest Res 2021;19:62-70. [PMID: 32375208 DOI: 10.5217/ir.2019.09156] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
187 Nguyen V, Kanth R, Gazo J, Sorrentino D. Management of post-operative Crohn's disease in 2017: where do we go from here? Expert Rev Gastroenterol Hepatol 2016;10:1257-69. [PMID: 27678049 DOI: 10.1080/17474124.2016.1241708] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
188 Tursi A, Elisei W, Picchio M, Giorgetti G, Brandimarte G. Accuracy of Rapid Fecal Calprotectin Test in Monitoring Inflammatory Bowel Diseases Under Treatment with TNFα Antagonists. Dig Dis Sci 2015;60:1406-13. [PMID: 25445163 DOI: 10.1007/s10620-014-3459-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
189 Lehmann FS, Burri E, Beglinger C. The role and utility of faecal markers in inflammatory bowel disease. Therap Adv Gastroenterol. 2015;8:23-36. [PMID: 25553077 DOI: 10.1177/1756283x14553384] [Cited by in Crossref: 95] [Cited by in F6Publishing: 37] [Article Influence: 13.6] [Reference Citation Analysis]
190 Weinstein-Nakar I, Focht G, Church P, Walters TD, Abitbol G, Anupindi S, Berteloot L, Hulst JM, Ruemmele F, Lemberg DA, Leach ST, Cytter R, Greer ML, Griffiths AM, Turner D; ImageKids study group. Associations Among Mucosal and Transmural Healing and Fecal Level of Calprotectin in Children With Crohn's Disease. Clin Gastroenterol Hepatol 2018; 16: 1089-1097. e4. [PMID: 29501599 DOI: 10.1016/j.cgh.2018.01.024] [Cited by in Crossref: 42] [Cited by in F6Publishing: 38] [Article Influence: 10.5] [Reference Citation Analysis]
191 Cozijnsen MA, Ben Shoham A, Kang B, Choe BH, Choe YH, Jongsma MME, Russell RK, Ruemmele FM, Escher JC, de Ridder L, Koletzko S, Martín-de-Carpi J, Hyams J, Walters T, Griffiths A, Turner D. Development and Validation of the Mucosal Inflammation Noninvasive Index For Pediatric Crohn's Disease. Clin Gastroenterol Hepatol 2020;18:133-140.e1. [PMID: 30981008 DOI: 10.1016/j.cgh.2019.04.012] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
192 Tontini GE, Vecchi M, Pastorelli L, Neurath MF, Neumann H. Differential diagnosis in inflammatory bowel disease colitis: State of the art and future perspectives. World J Gastroenterol 2015; 21(1): 21-46 [PMID: 25574078 DOI: 10.3748/wjg.v21.i1.21] [Cited by in CrossRef: 91] [Cited by in F6Publishing: 76] [Article Influence: 13.0] [Reference Citation Analysis]
193 Chang S, Malter L, Hudesman D. Disease monitoring in inflammatory bowel disease. World J Gastroenterol 2015; 21(40): 11246-11259 [PMID: 26523100 DOI: 10.3748/wjg.v21.i40.11246] [Cited by in CrossRef: 73] [Cited by in F6Publishing: 57] [Article Influence: 10.4] [Reference Citation Analysis]
194 Christensen B, Rubin DT. Understanding Endoscopic Disease Activity in IBD: How to Incorporate It into Practice. Curr Gastroenterol Rep 2016;18. [DOI: 10.1007/s11894-015-0477-6] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
195 Simioni J, Skare TL, Campos APB, Kotze L, Messias-Reason I, Ioshii SO, Nisihara R. Fecal Calprotectin, Gut Inflammation and Spondyloarthritis. Arch Med Res 2019;50:41-6. [PMID: 31101242 DOI: 10.1016/j.arcmed.2019.04.003] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
196 Boal Carvalho P, Rosa B, Dias de Castro F, Moreira MJ, Cotter J. PillCam COLON 2© in Crohn’s disease: A new concept of pan-enteric mucosal healing assessment. World J Gastroenterol 2015; 21(23): 7233-7241 [PMID: 26109810 DOI: 10.3748/wjg.v21.i23.7233] [Cited by in CrossRef: 33] [Cited by in F6Publishing: 35] [Article Influence: 4.7] [Reference Citation Analysis]
197 Moniuszko A, Wiśniewska A, Rydzewska G. Biomarkers in management of inflammatory bowel disease. Prz Gastroenterol. 2013;8:275-283. [PMID: 24868269 DOI: 10.5114/pg.2013.38728] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 0.3] [Reference Citation Analysis]
198 Klimczak K, Lykowska-Szuber L, Eder P, Krela-Kazmierczak I, Stawczyk-Eder K, Szymczak A, Michalak M, Studniarek A, Linke K. The diagnostic usefulness of fecal lactoferrin in the assessment of Crohn's disease activity. Eur J Intern Med. 2015;26:623-627. [PMID: 26198785 DOI: 10.1016/j.ejim.2015.06.015] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
199 van Tilburg MAL, Claar RL, Romano JM, Langer SL, Drossman DA, Whitehead WE, Abdullah B, Levy RL. Psychological Factors May Play an Important Role in Pediatric Crohn's Disease Symptoms and Disability. J Pediatr 2017;184:94-100.e1. [PMID: 28238483 DOI: 10.1016/j.jpeds.2017.01.058] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 4.0] [Reference Citation Analysis]
200 Raftery T, Merrick M, Healy M, Mahmud N, O'Morain C, Smith S, McNamara D, O'Sullivan M. Vitamin D Status Is Associated with Intestinal Inflammation as Measured by Fecal Calprotectin in Crohn's Disease in Clinical Remission. Dig Dis Sci 2015;60:2427-35. [PMID: 25757449 DOI: 10.1007/s10620-015-3620-1] [Cited by in Crossref: 40] [Cited by in F6Publishing: 36] [Article Influence: 5.7] [Reference Citation Analysis]
201 Ho S, Pothoulakis C, Koon HW. Antimicrobial peptides and colitis. Curr Pharm Des 2013;19:40-7. [PMID: 22950497 DOI: 10.2174/13816128130108] [Cited by in Crossref: 4] [Cited by in F6Publishing: 29] [Article Influence: 0.4] [Reference Citation Analysis]
202 af Björkesten C, Nieminen U, Turunen U, Arkkila P, Sipponen T, Färkkilä M. Surrogate markers and clinical indices, alone or combined, as indicators for endoscopic remission in anti-TNF-treated luminal Crohn's disease. Scandinavian Journal of Gastroenterology 2012;47:528-37. [DOI: 10.3109/00365521.2012.660542] [Cited by in Crossref: 109] [Cited by in F6Publishing: 104] [Article Influence: 10.9] [Reference Citation Analysis]
203 Ruemmele F, Veres G, Kolho K, Griffiths A, Levine A, Escher J, Amil Dias J, Barabino A, Braegger C, Bronsky J, Buderus S, Martín-de-carpi J, De Ridder L, Fagerberg U, Hugot J, Kierkus J, Kolacek S, Koletzko S, Lionetti P, Miele E, Navas López V, Paerregaard A, Russell R, Serban D, Shaoul R, Van Rheenen P, Veereman G, Weiss B, Wilson D, Dignass A, Eliakim A, Winter H, Turner D. Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn's disease. Journal of Crohn's and Colitis 2014;8:1179-207. [DOI: 10.1016/j.crohns.2014.04.005] [Cited by in Crossref: 580] [Cited by in F6Publishing: 470] [Article Influence: 72.5] [Reference Citation Analysis]
204 Deepak P, Fletcher JG, Fidler JL, Bruining DH. Computed Tomography and Magnetic Resonance Enterography in Crohn's Disease: Assessment of Radiologic Criteria and Endpoints for Clinical Practice and Trials. Inflamm Bowel Dis. 2016;22:2280-2288. [PMID: 27508513 DOI: 10.1097/mib.0000000000000845] [Cited by in Crossref: 27] [Cited by in F6Publishing: 10] [Article Influence: 6.8] [Reference Citation Analysis]
205 Chen JM, Liu T, Gao S, Tong XD, Deng FH, Nie B. Efficacy of noninvasive evaluations in monitoring inflammatory bowel disease activity: A prospective study in China. World J Gastroenterol 2017; 23(46): 8235-8247 [PMID: 29290660 DOI: 10.3748/wjg.v23.i46.8235] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 19] [Article Influence: 4.2] [Reference Citation Analysis]
206 Rubio MG, Amo-Mensah K, Gray JM, Nguyen VQ, Nakat S, Grider D, Love K, Boone JH, Sorrentino D. Fecal lactoferrin accurately reflects mucosal inflammation in inflammatory bowel disease. World J Gastrointest Pathophysiol 2019; 10(5): 54-63 [PMID: 31911845 DOI: 10.4291/wjgp.v10.i5.54] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
207 Swale A, Miyajima F, Roberts P, Hall A, Little M, Beadsworth MB, Beeching NJ, Kolamunnage-Dona R, Parry CM, Pirmohamed M. Calprotectin and lactoferrin faecal levels in patients with Clostridium difficile infection (CDI): a prospective cohort study. PLoS One 2014;9:e106118. [PMID: 25170963 DOI: 10.1371/journal.pone.0106118] [Cited by in Crossref: 28] [Cited by in F6Publishing: 30] [Article Influence: 3.5] [Reference Citation Analysis]
208 Wagner M, Sjöberg K, Vigren L, Olesen M, Benoni C, Toth E, Carlson M. Elevated fecal levels of eosinophil granule proteins predict collagenous colitis in patients referred to colonoscopy due to chronic non-bloody diarrhea. Scand J Gastroenterol 2016;51:835-41. [PMID: 26854205 DOI: 10.3109/00365521.2016.1141432] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
209 Beigel F, Deml M, Schnitzler F, Breiteneicher S, Göke B, Ochsenkühn T, Brand S. Rate and predictors of mucosal healing in patients with inflammatory bowel disease treated with anti-TNF-alpha antibodies. PLoS One 2014;9:e99293. [PMID: 24932476 DOI: 10.1371/journal.pone.0099293] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 2.4] [Reference Citation Analysis]
210 Feng JR, Qiu X, Wang F, Chen PF, Gao Q, Peng YN, Lin X, Liu Q, Liu J, Zhao Q, Li J. Diagnostic Value of Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio in Crohn's Disease. Gastroenterol Res Pract 2017;2017:3526460. [PMID: 28798770 DOI: 10.1155/2017/3526460] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 3.2] [Reference Citation Analysis]
211 Wu SY, Yang CH, Sun WL, Sun X, Zhang Y, Ge ZZ. Use of Advanced Modalities Does Not Guarantee Early Detection of Small-Bowel Crohn's Disease in the Absence of Complications. Med Sci Monit 2019;25:8704-11. [PMID: 31738744 DOI: 10.12659/MSM.918413] [Reference Citation Analysis]
212 Klenske E, Bojarski C, Waldner M, Rath T, Neurath MF, Atreya R. Targeting mucosal healing in Crohn's disease: what the clinician needs to know. Therap Adv Gastroenterol 2019;12:1756284819856865. [PMID: 31236140 DOI: 10.1177/1756284819856865] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 6.3] [Reference Citation Analysis]